Replies to post #95997 on Biotech Values

[Imclonian]

Onco:

Since 2000, when Reolysin first entered the clinic, Oncolytics has enrolled some 330 patients in multiple Phase 1 and 2 studies. “When we lump all indications together, you see this pattern, where people have a three-in-four chance of stabilizing or having a tumour regress fairly significantly. And an even higher percentage in metastatic lesions,” he adds.

Is this guy serious? Lump all indications together? lol, that's a joke. Whatever happened to doing several complete and proper trials to see the benefits. It seems to me that these guys are trying to cut corners and jumping into Phase III.